Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Metastasis | Review

E-cadherin on epithelial–mesenchymal transition in thyroid cancer

Authors: Xiaoyu Zhu, Xiaoping Wang, Yifei Gong, Junlin Deng

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Thyroid carcinoma is a common malignant tumor of endocrine system and head and neck. Recurrence, metastasis and high malignant expression after routine treatment are serious clinical problems, so it is of great significance to explore its mechanism and find action targets. Epithelial–mesenchymal transition (EMT) is associated with tumor malignancy and invasion. One key change in tumour EMT is low expression of E-cadherin. Therefore, this article reviews the expression of E-cadherin in thyroid cancers (TC), discuss the potential mechanisms involved, and outline opportunities to exploit E-cadherin on regulating the occurrence of EMT as a critical factor in cancer therapeutics.
Literature
1.
Liu Y, Lin Z, Sheng C, Zhu Y, Huang Y, Zhong N, Jia Z, Qu S. The prevalence of thyroid nodules in northwest China and its correlation with metabolic parameters and uric acid. Oncotarget. 2017;8(25):41555–62.PubMedPubMedCentralCrossRef
2.
Meixner M, et al. Disease-free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th classifications of T stage, and the prognostic value of primary tumour size. Nuklearmedizin. 2013;52(3):71–80.PubMedCrossRef
3.
De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.PubMedCrossRef
4.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.PubMedCrossRef
5.
Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol. 2003;19:207–35.PubMedCrossRef
6.
Gheldof A, Berx G. Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci. 2013;116:317–36.PubMedCrossRef
7.
Guillot C, Lecuit T. Mechanics of epithelial tissue homeostasis and morphogenesis. Science. 2013;340(6137):1185–9.PubMedCrossRef
8.
van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14(2):121–34.PubMedCrossRef
9.
Takeichi M. The cadherin superfamily in neuronal connections and interactions. Nat Rev Neurosci. 2007;8(1):11–20.PubMedCrossRef
10.
Tepass U, Truong K, Godt D, Ikura M, Peifer M. Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol. 2000;1(2):91–100.PubMedCrossRef
11.
Shrestha N, Chand L, Han MK, Lee SO, Kim CY, Jeong YJ. Glutamine inhibits CCl4 induced liver fibrosis in mice and TGF-β1 mediated epithelial–mesenchymal transition in mouse hepatocytes. Food Chem Toxicol. 2016;93:129–37.PubMedCrossRef
12.
Lourenco AR, Ban Y, Crowley MJ, Lee SB, Ramchandani D, Du W, Elemento O, George JT, Jolly MK, Levine H. Sheng, differential contributions of pre- and post-EMT tumor cells in breast cancer metastasis. Cancer Res. 2020;80(2):163–9.PubMedCrossRef
13.
Jensen K, et al. Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer. Exp Ther Med. 2010;1(3):457–62.PubMedPubMedCentralCrossRef
14.
Lv N, et al. The Expression of transcription factors is different in papillary thyroid cancer cells during TNF-alpha induced EMT. J Cancer. 2021;12(9):2777–86.PubMedPubMedCentralCrossRef
15.
Sastre-Perona A, Santisteban P. Role of the wnt pathway in thyroid cancer. Front Endocrinol. 2012;3:31.CrossRef
16.
Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010;16(12):3153–62.PubMedCrossRef
17.
18.
Zhao C, et al. FOXN3 suppresses the growth and invasion of papillary thyroid cancer through the inactivation of Wnt/β-catenin pathway. Mol Cell Endocrinol. 2020;515: 110925.PubMedCrossRef
19.
Wu L, et al. Expression of lncRNA-HOTAIR in the serum of patients with lymph node metastasis of papillary thyroid carcinoma and its impact. Oncol Lett. 2020;20(1):907–13.PubMedPubMedCentralCrossRef
20.
21.
van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65(23):3756–88.PubMedCrossRef
22.
Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial–mesenchymal transition in solid tumors. BMC Cancer. 2012;12:35.PubMedPubMedCentralCrossRef
23.
Cho SW, Kim YA, Sun HJ, Ahn HY, Lee EK, Yi KH, Oh BC, Park DJ, Cho BY, Park YJ. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling. J Clin Endocrinol Metab. 2014;99(9):1641–9.CrossRef
24.
Cho SW, Lee EJ, Kim H, Kim SH, Ahn HY, Kim YA, Yi KH, Park DJ, Shin CS, Ahn SH, Cho BY. Dickkopf-1 inhibits thyroid cancer cell survival and migration through regulation of β-catenin/E-cadherin signaling. Mol Cell Endocrinol. 2013;366(1):90–8.PubMedCrossRef
25.
26.
Jiang BH, Liu LZ. Chapter 2 PI3K/PTEN signaling in angiogenesis and tumorigenesis. 2009. p. 19–65.
27.
28.
29.
Wang SC, et al. HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway. Biomed Pharmacother. 2015;75:33–9.PubMedCrossRef
30.
Sun Y, Ye D, Li Y, Chen E, Hao R, Cai Y, Wang Q, Wang O, Zhang X. CUX2 functions as an oncogene in papillary thyroid cancer. Onco Targets Ther. 2018;12:217–24.PubMedPubMedCentralCrossRef
31.
32.
Xiong J, et al. Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN. Exp Cell Res. 2017;361(2):316–23.PubMedCrossRef
33.
Ramirez-Moya J, Wert-Lamas L, Santisteban P. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN. Oncogene. 2018;37(25):3369–83.PubMedCrossRef
34.
Gao W, Han J. Overexpression of ING5 inhibits HGF-induced proliferation, invasion and EMT in thyroid cancer cells via regulation of the c-Met/PI3K/Akt signaling pathway. Biomed Pharmacother. 2018;98:265–70.PubMedCrossRef
35.
Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, Van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003;63(9):2172–8.PubMed
36.
Guigon CJ, et al. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene. 2009;28(4):509–17.PubMedCrossRef
37.
Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001;61(16):6105–11.PubMed
38.
Zhao L, Jiang R, Xu M, Zhu P, Mo XM, Wang N, Chen GG, Liu ZM. Concomitant high expression of BRAFV 600E, P-cadherin and cadherin 6 is associated with high TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma. Clin Endocrinol. 2016;84(5):748–55.CrossRef
39.
Shimamura M, et al. Acceleration of BRAF(V600E)-induced thyroid carcinogenesis by TGFβ signal deficiency in mice. Endocrine. 2020;69(3):571–7.PubMedCrossRef
40.
Fujishita MAT. Oncogenic Roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153–89.PubMed
41.
Xia P, Xu XY. PI3K Akt mTOR signaling pathway in cancer stem cells from basic research to clinical application. Am J Cancer Res. 2015;5(5):1602–9.PubMedPubMedCentral
42.
Vara JÁ, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193–204.CrossRef
43.
Noorolyai S, et al. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120–8.PubMedCrossRef
44.
Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia. 2008;22(4):686–707.PubMedCrossRef
45.
Ramírez-Moya J, Wert-Lamas L, Santisteban P. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN. Oncogene. 2018;37(25):3369–83.PubMedCrossRef
46.
Sun C, et al. F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT. Biomed Pharmacother. 2018;98:416–23.PubMedCrossRef
47.
Wang L, et al. Deltex3 inhibits epithelial mesenchymal transition in papillary thyroid carcinoma via promoting ubiquitination of XRCC5 to regulate the AKT signal pathway. J Cancer. 2021;12(3):860–73.PubMedPubMedCentralCrossRef
48.
Lv J, et al. M2like tumourassociated macrophagesecreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway. Mol Med Rep. 2021;24(2):1–10.CrossRef
49.
50.
Brzezianska E, Pastuszak-Lewandoska D. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. Front Biosci. 2021;16:422–39.CrossRef
51.
Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):153–83.PubMed
52.
53.
54.
Lin X, et al. TFF3 contributes to epithelial–mesenchymal transition (EMT) in papillary thyroid carcinoma cells via the MAPK/ERK signaling pathway. J Cancer. 2018;9(23):4430–9.PubMedPubMedCentralCrossRef
55.
Xie F, et al. TGF-beta signaling in cancer metastasis. Acta Biochim Biophys Sin. 2018;50(1):121–32.PubMedCrossRef
56.
Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harbor Perspect Biol. 2016;8(5): a021873.CrossRef
57.
58.
Hao Y, Baker D, Ten Dijke P. TGF-beta-mediated epithelial–mesenchymal transition and cancer metastasis. Int J Mol Sci. 2019;20(11):2767.PubMedCentralCrossRef
59.
Baquero P, Jiménez-Mora E, Santos A, Lasa M, Chiloeches A. TGFβ induces epithelial–mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways. Mol Carcinog. 2016;55(11):1639–54.PubMedCrossRef
60.
Kim DW, et al. Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model. Carcinogenesis. 2013;34(10):2389–400.PubMedPubMedCentralCrossRef
61.
Bhatti MZ, et al. REGγ potentiates TGF-β/Smad signal dependent epithelial–mesenchymal transition in thyroid cancer cells. Cell Signal. 2019;64: 109412.PubMedCrossRef
62.
Min WP, Wei XF. Silencing SIX1 inhibits epithelial mesenchymal transition through regulating TGF-β/Smad2/3 signaling pathway in papillary thyroid carcinoma. Auris Nasus Larynx. 2020;48(3):487–95.PubMedCrossRef
63.
Li T, et al. Epigallocatechin gallate (EGCG) suppresses epithelial–mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways. Bioengineered. 2019;10(1):282–91.PubMedPubMedCentralCrossRef
64.
Baquero P, et al. TGFβ induces epithelial–mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways. Mol Carcinog. 2016;55(11):1639–54.PubMedCrossRef
65.
Wieczorek-Szukala K, et al. Snail-1 overexpression correlates with metastatic phenotype in BRAF(V600E) positive papillary thyroid carcinoma. J Clin Med. 2020;9(9):2701.PubMedCentralCrossRef
66.
67.
68.
Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263–6.PubMedCrossRef
69.
Li H, et al. The tumor microenvironment: an irreplaceable element of tumor budding and epithelial–mesenchymal transition-mediated cancer metastasis. Cell Adhes Migr. 2016;10(4):434–46.CrossRef
70.
71.
Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol. 2010;176:2972–85.PubMedPubMedCentralCrossRef
72.
Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.PubMedCrossRef
73.
Coussens LM, Zitvogel L, Palucka A. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;6117(339):286–91.CrossRef
74.
75.
Yan Y, et al. High tumor-associated macrophages infiltration is associated with poor prognosis and may contribute to the phenomenon of epithelial–mesenchymal transition in gastric cancer. Onco Targets Ther. 2016;9:3975–83.PubMedPubMedCentralCrossRef
76.
77.
Hu Y, et al. Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J Exp Clin Cancer Res. 2016;35:12.PubMedPubMedCentralCrossRef
78.
Lv J, et al. M2-like tumor-associated macrophages-secreted Wnt1 and Wnt3a promotes dedifferentiation and metastasis via activating beta-catenin pathway in thyroid cancer. Mol Carcinog. 2021;60(1):25–37.PubMedCrossRef
79.
Lin X, et al. miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization. J Hematol Oncol. 2019;12(1):20.PubMedPubMedCentralCrossRef
80.
Chen Y, Wen H, Zhou C, Su Q, Lin Y, Xie Y, Huang Y, Qiu Q, Lin J, Huang X, Tan W. TNF-α derived from M2 tumor-associated macrophages promotes epithelial–mesenchymal transition and cancer stemness through the Wnt/β-catenin pathway in SMMC-7721 hepatocellular carcinoma cells. Exp Cell Res. 2019;378(1):41–50.PubMedCrossRef
81.
Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1977;77(4):1033–79.CrossRef
82.
Mekori YA. The mastocyte: the “other” inflammatory cell in immunopathogenesis. J Allergy Clin Immunol. 2004;114(1):52–7.PubMedCrossRef
83.
Okano M, et al. Triple-negative breast cancer with high levels of annexin A1 expression is associated with mast cell infiltration, inflammation, and angiogenesis. Int J Mol Sci. 2019;20(17):4197.PubMedCentralCrossRef
84.
Melillo RM, et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29(47):6203–15.PubMedCrossRef
85.
Visciano C, Liotti F, Prevete N, Franco R, Collina F, De Paulis A, Marone G, Santoro M, Melillo RM. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene. 2015;34(40):5175–86.PubMedCrossRef
86.
87.
88.
Aghajani MJ, et al. Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer. Endocr Connect. 2020;9(10):1028–41.PubMedPubMedCentralCrossRef
89.
90.
91.
Alsuliman A, et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer. 2015;14:149.PubMedPubMedCentralCrossRef
92.
93.
Sánchez-Tilló E, Siles L, De Barrios O, Cuatrecasas M, Vaquero EC, Castells A, Postigo A. Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res. 2011;7(1):897.
94.
Rosenbloom KR, et al. The UCSC genome browser database: 2015 update. Nucleic Acids Res. 2015;43(Database issue):D670–6781.PubMedCrossRef
95.
Chen L, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.PubMedCrossRef
96.
Noda K, Miyoshi E, Uozumi N, Gao CX, Suzuki K, Hayashi N, Hori M, Taniguchi N. High expression of alpha-1-6 fucosyltransferase during rat hepatocarcinogenesis. Int J Cancer. 1998;3(75):444–50.CrossRef
97.
Miyoshi E, Uozumi N, Noda K, Hayashi N, Hori M, Taniguchi N. Expression of alpha1-6 fucosyltransferase in rat tissues and human cancer cell lines. Int J Cancer. 1997;6(72):1117–21.CrossRef
98.
Ito Y, Miyauchi A, Yoshida H, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, et al. Expression of α1,6-fucosyltransferase (FUT8) in papillary carcinoma of the thyroid: its linkage to biological aggressiveness and anaplastic transformation. Cancer Lett. 2003;2(200):167–72.CrossRef
99.
Osumi D, Takahashi M, Miyoshi E, Yokoe S, Lee SH, Noda K, Nakamori S, Gu J, Ikeda Y, Kuroki Y, Sengoku K, Ishikawa M, Taniguchi N. Core fucosylation of E-cadherin enhances cell–cell adhesion in human colon carcinoma WiDr cells. Cancer Sci. 2009;5(100):888–95.CrossRef
100.
Ma M, et al. Fucosyltransferase 8 regulation and breast cancer suppression by transcription factor activator protein 2gamma. Cancer Sci. 2021;112(8):3190–204.PubMedPubMedCentralCrossRef
101.
Fei GE, Shi BZ, Yuan YF, Wu XZ. The expression of core fucosylated E-cadherin in cancer cells and lung cancer patients: prognostic implications. Cell Res. 2004;5(14):423–33.
102.
Okada M, Chikuma S, Kondo T, Hibino S, Machiyama H, Yokosuka T, Nakano M, Yoshimura A. Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells. Cell Rep. 2017;5(20):1017–28.CrossRef
103.
Fuxe J, Karlsson MC. TGF-β-induced epithelial–mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol. 2012;5–6(22):455–61.CrossRef
104.
DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54–67.PubMedPubMedCentralCrossRef
105.
Baghdadi M, et al. Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res. 2016;76(20):6030–42.PubMedCrossRef
106.
Zhou SL, et al. miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology. 2016;63(5):1560–75.PubMedCrossRef
107.
108.
109.
Nilsson M, Husmark J, Bjorkman U, Ericson LE. Cytokines and thyroid epithelial integrity: interleukin-1α induces dissociation of the junctional complex and paracellular leakage in filter-cultured human thyrocytes. J Clin Endocrinol Metab. 1998;3(83):945–52.
110.
111.
112.
113.
Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, et al. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer. 2011;6(18):669–85.CrossRef
114.
Lv N, Shan Z, Gao Y, et al. Twist1 regulates the epithelial–mesenchymal transition via the NF-κB pathway in papillary thyroid carcinoma. Endocrine. 2016;3(51):469–77.CrossRef
115.
Li H, Chen A, Yuan Q, Chen W, Zhong H, Teng M, Xu C, Qiu Y, Cao J. NF-κB/Twist axis is involved in chysin inhibition of ovarian cancer stem cell features induced by co-treatment of TNF-α and TGF-β. Int J Clin Exp Pathol. 2019;1(12):101–12.
116.
Lv N, et al. Twist1 regulates the epithelial–mesenchymal transition via the NF-κB pathway in papillary thyroid carcinoma. Endocrine. 2016;51(3):469–77.PubMedCrossRef
117.
118.
You A, et al. MicroRNA-203 restrains epithelial–mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3. Cell Cycle. 2020;19(10):1105–21.PubMedPubMedCentralCrossRef
119.
Wen HL, et al. miR-597-3p inhibits invasion and migration of thyroid carcinoma SW579 cell by targeting RAB23. Endokrynol Pol. 2020;72(1):22–8.PubMedCrossRef
120.
Tamagawa S, et al. MicroRNA 200b promotes mesenchymal-to-epithelial transition in anaplastic thyroid carcinoma. Oncol Lett. 2020;20(4):3.PubMedPubMedCentral
121.
Li Y, Zeng QG, Qiu JL, Pang T, Wang H, Zhang XX. Propofol suppresses migration, invasion, and epithelial–mesenchymal transition in papillary thyroid carcinoma cells by regulating miR-122 expression. Eur Rev Med Pharmacol Sci. 2020;24(9):5101–10.PubMed
122.
Hardin H, et al. The roles of the epithelial–mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol. 2014;184(8):2342–54.PubMedPubMedCentralCrossRef
123.
Liu C, et al. MiR-144-3p promotes the tumor growth and metastasis of papillary thyroid carcinoma by targeting paired box gene 8. Cancer Cell Int. 2018;18:54.PubMedPubMedCentralCrossRef
124.
Zhang X, et al. MicroRNA 483-3p targets Pard3 to potentiate TGF-beta1-induced cell migration, invasion, and epithelial–mesenchymal transition in anaplastic thyroid cancer cells. Oncogene. 2019;38(5):699–715.PubMedCrossRef
125.
Wang DP, et al. microRNA-599 promotes apoptosis and represses proliferation and epithelial–mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-depentent Notch signaling pathway. J Cell Physiol. 2020;235(3):2492–505.PubMedCrossRef
126.
Wang Y, Liu BG, Zhou CX. MicroRNA-31 inhibits papillary thyroid carcinoma cell biological rogression by directly targeting SOX11 and egulating epithelial-to-mesenchymal transition, ERK and Akt signaling pathways. Eur Rev Med Pharmacol Sci. 2019;23(13):5863–73.PubMed
127.
Hao F, et al. miR-199a-5p suppresses epithelial–mesenchymal-transition in anaplastic thyroid carcinoma cells via targeting Snail signals. Cancer Biomark. 2020;29(3):317–26.PubMedCrossRef
128.
Hong S, et al. MiR-20b displays tumor-suppressor functions in papillary thyroid carcinoma by regulating the MAPK/ERK signaling pathway. Thyroid. 2016;26(12):1733–43.PubMedCrossRef
129.
Ren L, et al. miR-199b-5p-Stonin 2 axis regulates metastases and epithelial-to-mesenchymal transition of papillary thyroid carcinoma. IUBMB Life. 2019;71(1):28–40.PubMedCrossRef
130.
Han J, et al. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3beta/Snail signaling by targeting ARFGEF1. Cell Death Dis. 2019;10(3):195.PubMedPubMedCentralCrossRef
131.
Fan X, Zhao Y. miR-451a inhibits cancer growth, epithelial–mesenchymal transition and induces apoptosis in papillary thyroid cancer by targeting PSMB8. J Cell Mol Med. 2019;23(12):8067–75.PubMedPubMedCentralCrossRef
132.
Huang Y, et al. MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2. Cancer Cell Int. 2021;21(1):494.PubMedPubMedCentralCrossRef
133.
Pan XM, He XY, Yang YL, Jia WJ, Yang ZQ, Yan D, Ma JX. MiR-630 inhibits papillary thyroid carcinoma cell growth, metastasis, and epithelial–mesenchymal transition by suppressing JAK2 STAT3 signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(6):2453–60.PubMed
134.
135.
136.
He H, Yang H, Liu D, Pei R. LncRNA NORAD promotes thyroid carcinoma rogression through targeting miR-202-5p. Am J Transl Res. 2019;11(1):290–9.PubMedPubMedCentral
137.
Xia S, Ji R, Zhan W. Long noncoding RNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) inhibits proliferation and invasion of glioma cells by suppressing the Wnt/beta-catenin signaling pathway. BMC Neurol. 2017;17(1):30.PubMedPubMedCentralCrossRef
138.
Wang DP, et al. Overexpression of long noncoding RNA SLC26A4-AS1 inhibits the epithelial–mesenchymal transition via the MAPK pathway in papillary thyroid carcinoma. J Cell Physiol. 2020;235(3):2403–13.PubMedCrossRef
139.
Zhang R, et al. Long non-coding RNA Linc-ROR is upregulated in papillary thyroid carcinoma. Endocr Pathol. 2018;29(1):1–8.PubMedCrossRef
140.
Feng J, et al. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3. Cell Death Dis. 2019;10(6):433.PubMedPubMedCentralCrossRef
141.
Wang XJ, et al. LINC00106 prevents against metastasis of thyroid cancer by inhibiting epithelial–mesenchymal transition. Eur Rev Med Pharmacol Sci. 2020;24(19):10015–21.PubMed
142.
Zhou T, et al. LncRNA CASC2 expression is down-regulated in papillary thyroid cancer and promotes cell invasion by affecting EMT pathway. Cancer Biomark. 2018;23(2):185–91.PubMedCrossRef
143.
Pellecchia S, et al. The long non-coding RNA Prader Willi/Angelman region RNA5 (PAR5) is downregulated in anaplastic thyroid carcinomas where it acts as a tumor suppressor by reducing EZH2 activity. Cancers. 2020;12(1):235.PubMedCentralCrossRef
144.
Wang Y, et al. lncRNA BANCR promotes EMT in PTC via the Raf/MEK/ERK signaling pathway. Oncol Lett. 2018;15(4):5865–70.PubMedPubMedCentral
145.
Zhang R, et al. MALAT1 long non-coding RNA expression in thyroid tissues: analysis by in situ hybridization and real-time PCR. Endocr Pathol. 2017;28(1):7–12.PubMedPubMedCentralCrossRef
146.
Li D, Hao S, Zhang J. Long non-coding RNA UCA1 exerts growth modulation by miR-15a in human thyroid cancer TPC-1 cells. Artif Cells Nanomed Biotechnol. 2019;47(1):1815–22.PubMedCrossRef
147.
Lei H, Gao Y, Xu X. LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145. Acta Biochim Biophys Sin. 2017;49(7):588–97.PubMedCrossRef
148.
Chen D, et al. Knockdown of LINC02471 inhibits papillary thyroid carcinoma cell invasion and metastasis by targeting miR-375. Cancer Manag Res. 2020;12:8757–71.PubMedPubMedCentralCrossRef
149.
Xia E, et al. lncRNA LINC00673 induces proliferation, metastasis and epithelial–mesenchymal transition in thyroid carcinoma via Kruppel-like factor 2. Int J Oncol. 2018;53(5):1927–38.PubMedPubMedCentral
150.
Gupta A, Williams BR, Hanash SM, Rawwas J. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma. Cancer Res. 2006;66:8100–8.PubMedCrossRef
151.
Zhao H, et al. LINC01816 promotes the migration, invasion and epithelial–mesenchymal transition of thyroid carcinoma cells by sponging miR34c5p and regulating CRABP2 expression levels. Oncol Rep. 2021;45(5):1–12.PubMedPubMedCentralCrossRef
152.
Wang X-J, Zheng H-T, Xu J, Guo Y-W, Zheng G-B, Ma C, Hao S-L, Liu X-C, Chen H-J, Wei S-J, Wu G-C. LINC00106 prevents against metastasis of thyroid cancer by inhibiting epithelial–mesenchymal transition. Eur Rev Med Pharmacol Sci. 2020;24(19):10015–21.PubMed
153.
Zhao X, Hu X. Downregulated long noncoding RNA LINC00313 inhibits the epithelial–mesenchymal transition, invasion, and migration of thyroid cancer cells through inhibiting the methylation of ALX4. J Cell Physiol. 2019;234(11):20992–1004.PubMedCrossRef
154.
Wang G, Le Y, Wei L. Cheng L CREB3 transactivates lncRNA ZFAS1 to promote papillary thyroid carcinoma metastasis by modulating miR-373-3p/MMP3 regulatory axis. Int J Endocrinol. 2021;2021: 9981683.PubMedPubMedCentralCrossRef
155.
156.
157.
Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial–mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15(2):201–12.PubMedPubMedCentralCrossRef
158.
Gao H, et al. Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer. Tumour Biol. 2017;39(5):1010428317698368.PubMedCrossRef
159.
Jablonska-Trypuc A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31(sup1):177–83.PubMedCrossRef
160.
161.
Agraval H, Yadav UC. MMP-2 and MMP-9 mediate cigarette smoke extract-induced epithelial–mesenchymal transition in airway epithelial cells via EGFR/Akt/GSK3beta/beta-catenin pathway: amelioration by fisetin. Chem Biol Interact. 2019;314: 108846.PubMedCrossRef
162.
163.
164.
165.
Da C, Wu K, Yue C, Bai P, Wang R, Wang G, Zhao M, Lv Y, Hou P. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways. Oncotarget. 2017;8(5):8131–42.PubMedCrossRef
166.
Calì G, et al. CDH16/Ksp-cadherin is expressed in the developing thyroid gland and is strongly down-regulated in thyroid carcinomas. Endocrinology. 2012;153(1):522–34.PubMedCrossRef
167.
Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol. 2005;21:381–410.PubMedCrossRef
168.
Casal JI, Bartolome RA. Beyond N-cadherin, relevance of cadherins 5, 6 and 17 in cancer progression and metastasis. Int J Mol Sci. 2019;20(13):3373.PubMedCentralCrossRef
169.
Zhou Y, et al. Downregulated CDH3 decreases proliferation, migration, and invasion in thyroid cancer. Am J Transl Res. 2020;12(6):3057–67.PubMedPubMedCentral
170.
Gugnoni M, et al. Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy. Oncogene. 2017;36(5):667–77.PubMedCrossRef
171.
Guixia W, Liwei Z. Advances of relationship between E-cadherin and gastric cancer. BME Clin Med. 2019;23(2):230–4.
172.
Shuping Z, Wenjie T, Peng W. Serum E-cad and clinic pathological factors in patients with papillary thyroid carcinoma. China Health Stand Manage. 2020;11(20):122–4.
173.
Na HY, et al. Expression of class III beta-tubulin is associated with invasive potential and poor prognosis in thyroid carcinoma. J Clin Med. 2020;9(12):3830.PubMedCentralCrossRef
174.
El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol. 2008;3:5.PubMedPubMedCentralCrossRef
175.
Haugen BR, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.PubMedPubMedCentralCrossRef
176.
Cho SW, et al. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling. J Clin Endocrinol Metab. 2014;99(9):E1641–9.PubMedCrossRef
177.
Cho SW, et al. Dickkopf-1 inhibits thyroid cancer cell survival and migration through regulation of β-catenin/E-cadherin signaling. Mol Cell Endocrinol. 2013;366(1):90–8.PubMedCrossRef
178.
Cho NL, Lin CI, Whang EE, Carothers AM, Moore FD Jr, Ruan DT. Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation. Thyroid. 2010;20(6):615–22.PubMedCrossRef
179.
Wang N, Wen J, Ren W, Wu Y, Deng C. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF V600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib. Cancer Chemother Pharmacol. 2021;88(1):155–64.PubMedCrossRef
180.
Park CH, et al. Combined effects of baicalein and docetaxel on apoptosis in 8505c anaplastic thyroid cancer cells via downregulation of the ERK and Akt/mTOR pathways. Endocrinol Metab. 2018;33(1):121–32.CrossRef
181.
182.
Sherman EJ, et al. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer. 2017;123(21):4114–21.PubMedCrossRef
183.
Park J, Jung HA, Shim JH, Park WY, Kim TH, Lee SH, Kim SW, Ahn MJ, Park K, Chung JH. Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. Eur J Endocrinol. 2021;184(6):837–45.PubMedCrossRef
184.
Corcoran RB, André T, Atreya CE, Schellens JH, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O’Dwyer PJ, Humblet Y, De Vosi F, ScottJung A, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov. 2018;8(4):428–43.PubMedPubMedCentralCrossRef
185.
186.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JH, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13.PubMedCrossRef
187.
Planchard D, Smit EF, Groen HJ, Mazieres J, Besse B, Helland Å, Giannone V, D’Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–16.PubMedCrossRef
188.
Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res. 2014;20(8):2035–43.PubMedCrossRef
189.
Xiong L, et al. Biological implications of PTEN upregulation and altered sodium/iodide symporter intracellular distribution in resveratrol-suppressed anaplastic thyroid cancer cells. J Cancer. 2020;11(23):6883–91.PubMedPubMedCentralCrossRef
190.
De Amicis F, et al. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013;228(10):2054–62.PubMedCrossRef
191.
Liang W, et al. Combretastatin A4 regulates proliferation, migration, invasion, and apoptosis of thyroid cancer cells via PI3K/Akt signaling pathway. Med Sci Monit. 2016;22:4911–7.PubMedPubMedCentralCrossRef
192.
193.
Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2016;22(4):807–12.PubMedCrossRef
194.
195.
Hellmann MD, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31.PubMedCrossRef
196.
Ferris RL, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45–51.PubMedPubMedCentralCrossRef
197.
Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360: k793.PubMedPubMedCentralCrossRef
198.
Ryder M, et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15(4):1069–74.PubMedPubMedCentralCrossRef
199.
Lv J, et al. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway. Life Sci. 2020;256: 117925.PubMedCrossRef
Metadata
Title
E-cadherin on epithelial–mesenchymal transition in thyroid cancer
Authors
Xiaoyu Zhu
Xiaoping Wang
Yifei Gong
Junlin Deng
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02344-6

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary research

UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways

Primary Research

Prognostic role of METTL1 in glioma

Primary research

Dysregulation of the miR-30a/BiP axis by cigarette smoking accelerates oral cancer progression

Correction

Correction to: LINC00514 upregulates CCDC71L to promote cell proliferation, migration and invasion in triple‐negative breast cancer by sponging miR-6504-5p and miR-3139

Review

Adeno‐associated virus (AAV)-based gene therapy for glioblastoma

Primary research

Calculated identification of mutator-derived lncRNA signatures of genomic instability to predict the clinical outcome of muscle-invasive bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits